FDA grants accelerated approval for Alzheimer’s disease treatment


6 January 2023 - Today, the US FDA approved Leqembi (lecanemab-irmb) via the accelerated approval pathway for the treatment of Alzheimer’s disease. 

Leqembi is the second of a new category of medications approved for Alzheimer’s disease that target the fundamental pathophysiology of the disease.

Read FDA press release

Michael Wonder

Posted by:

Michael Wonder